Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice

Behavioural Brain Research

Volumn 240, Issue 1, 2013, Pages 146-152

  Laursen, Bettina ^a,b   Mørk, Arne ^a   Plath, Niels ^a   Kristiansen, Uffe ^b   Bastlund, Jesper Frank ^a  

^a H LUNDBECK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Acetylcholine; Alzheimer's disease; Amyloid peptide; Mice; Mu p75 saporin; T CAT

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN PROTEIN; CHOLINE ACETYLTRANSFERASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEGENERATION; BRAIN TISSUE; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; DISEASE ASSOCIATION; ENZYME ACTIVITY; FRONTAL CORTEX; HIPPOCAMPUS; LEFT HEMISPHERE; MALE; MENTAL DETERIORATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION KINETICS; RIGHT HEMISPHERE; SENILE PLAQUE; WILD TYPE; WORKING MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CHOLINE O-ACETYLTRANSFERASE; CHOLINERGIC NEURONS; DISEASE MODELS, ANIMAL; FRONTAL LOBE; HIPPOCAMPUS; IMMUNOTOXINS; INJECTIONS, INTRAVENTRICULAR; MALE; MEMORY, SHORT-TERM; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID; PRESENILIN-1; RIBOSOME INACTIVATING PROTEINS, TYPE 1;

EID: 84871397626     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.11.012     Document Type: Article

References (69)

1. Pákáski M., Kálmán J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochemistry International 2008, 53:103-111.
2. Bayles K.A. Effects of working memory deficits of communicative functioning of Alzheimer's dementia patients. Journal of Communication Disorders 2003, 35:209-219.
3. Price D.L., Sisodia S.S. Mutant genes in familial Alzheimer's disease and transgenic models. Annual Review of Neuroscience 1998, 21:479-505.
4. Jankowsky J.L., Slunt H.H., Ratovitsky T., Jenkins N.A., Copeland N.G., Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomolecular Engineering 2001, 17:157-165.
5. Wang J., Tanila H., Puoliväli J., Kadish I., van Groen T. Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice. Neurobiology of Disease 2003, 14:318-327.
6. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Human Molecular Genetics 2004, 13:159-170.
7. Minkeviciene R., Ihalainen J., Malm T., Matilainen O., Keksa-Goldsteine V., Goldsteins G., et al. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. Journal of Neurochemistry 2008, 105:584-594.
8. Jardanhazi-Kurutz D., Kummer M.P., Terwel D., Vogel K., Dyrks T., Thiele A., et al. degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochemistry International 2010, 57:375-382.
9. Frye C.A., Walf A.A. Effects of progesterone administration and APPswe+PSEN1Δe9 mutation for cognitive performance of mid-aged mice. Neurobiology of Learning and Memory 2008, 89:17-26.
10. Reiserer R.S., Harrison F.E., Syverud D.C., McDonald M.P. Impaired spatial learning in the APPSwe+PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes, Brain and Behavior 2007, 6:54-65.
11. Savonenco A., Xu G.M., Melnikova T., Morton J.L., Gonzales V., Wong M.P.F., et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Relationships to β-amyloid deposition and neurotransmitter abnormalities. Neurobiology of Disease 2005, 18:602-617.
12. Radde R., Duma C., Goedert M., Jucker M. The value of incomplete mouse models of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging 2008, 35:70-74.
13. Roßner S. Cholinergic immunolesions by 192IGG-saporin - a useful tool to simulate pathogenic aspects of Alzheimer's disease. International Journal of Developmental Neuroscience 1997, 15:835-850.
14. Baddeley A.D., Bressi S., Della Sala S., Logie R., Spinnler H. The decline of working memory in Alzheimer's disease. A longitudinal study. Brain 1991, 114:2521-2542.
15. Lidow M.S., Koh P.-O., Arnsten A.F.T. D1 dopamine receptors in the mouse prefrontal cortex: Immunocytochemical and cognitive neuropharmacological analyses. Synapse 2003, 47:101-108.
16. Clausen B., Schachtman T.R., Mark L.T., Reinholdt M., Christoffersen G.R.J. Impairments of exploration and memory after systemic or prelimbic D1-receptor antagonism in rats. Behavioural Brain Research 2011, 223:241-254.
17. Christoffersen G.R.J., Simonyi A., Schachtman T.R., Clausen B., Clement D., Bjerre V.K., et al. MGlu5 antagonism impairs exploration and memory of spatial and non-spatial stimuli in rats. Behavioural Brain Research 2008, 191:235-345.
18. Baxter M.G., Chiba A.A. Cognitive functions of the basal forebrain. Current Opinion in Neurobiology 1999, 9:178-183.
19. Sarter M., Bruno J.P. Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Research Reviews 1997, 23:28-46.
20. Lalonde R. The neurobiological basis of spontaneous alternation. Neuroscience and Biobehavioral Reviews 2002, 26:91-104.
21. Iachini I., Iavarone A., Senese V.P., Ruotolo F., Ruggiero G. Visuospatial memory in healthy elderly, AD, and MCI: a review. Current Aging Science 2009, 2:43-59.
22. Cave C.B., Squire L.R. Equivalent impairment of spatial and nonspatial memory following damage to the human hippocampus. Hippocampus 1991, 1:329-340.
23. Beach T.G., Kuo Y.-M., Spiegel K., Emmerling M.R., Sue L.I., Kokjohn K., et al. The cholinergic deficit coincides with Aβ deposition at the earliest histopathologic stages of Alzheimer disease. Journal of Neuropathology and Experimental Neurology 2000, 59:308-313.
24. Gerlai R. A new continuous alternation task in T-maze detects hippocampal dysfunction in mice. A strain comparison and lesion study. Behavioural Brain Research 1998, 95(1):91-101.
25. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 1997, Academic Press, San Diego.
26. Spowart-Manning L., van der Staay F.J. The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse. Behavioural Brain Research 2004, 151:37-46.
27. Dong H.W. The Allen Reference Atlas: a digital color brain atlas of the C57BL/6J male mouse 2008, John Wiley & Sons, New Jersey.
28. Fonnum J. A rapid radiochemical method for the determination of choline acetyltransferase. Journal of Neurochemistry 1975, 24:407-409.
29. Mogensen J., Divac I. Behavioural changes after ablation of subdivisions of the rat prefrontal cortex. Acta Neurobiologiae Experimentalis 1993, 53:439-449.
30. Roberts W.W., Dember W.N., Brodwick M. Alternation and exploration in rats with hippocampal lesions. Journal of Comparative and Physiological Psychology 1962, 55:695-700.
31. Didic M., Barbeau E.J., Felician O., Tramoni E., Guedj E., Poncet M., et al. Which memory system is impaired first in Alzheimer's disease?. Journal of Alzheimer's Disease 2001, 27:11-22.
32. Lange K.W., Sahakian B.J., Quinn N.P., Marsden C.D., Robbins T.W. Comparison of executive and visuospatial memory function in Huntington's disease and dementia of Alzheimer type matched for degree of dementia. Journal of Neurology 1995, 58:598-606.
33. Chappell J., McMahan R., Chiba A., Gallagher M. A re-examination of the role of basal forebrain cholinergic neurons in spatial working memory. Neuropharmacology 1998, 37:481-487.
34. Moreau P.-H., Cosquer B., Jeltsch H., Cassel J.-C., Mathis C. Neuroanatomical and behavioural effects of a novel version of the cholinergic immunotoxin mu p75-saporin in mice. Hippocampus 2008, 18:610-622.
35. Nordberg A. Neuroreceptor changes in Alzheimer disease. Cerebrovascular and Brain Metabolism Reviews 1992, 4:303-328.
36. Mattsson A., Olson L., Svensson T.H., Schilström B. Cortical cholinergic deficiency enhances amphetamine-induced dopamine release in the accumbens but not striatum. Experimental Neurology 2007, 208(1):73-79.
37. Waite J.J., Wardlow M.L., Chen A.C., Lappi D.A., Wiley R.G., Thal L.J. Time course of cholinergic and monoaminergic changes in rat brain after immunolesioning with 192 IgG-saporin. Neuroscience Letters 1994, 169(1-2):154-158.
38. Martorana A., Mori F., Esposito Z., Kusayanagi H., Monteleone F., Codecà C., et al. Dopamine modulates cholinergic cortical excitability in Alzheimer's disease patients. Neuropsychopharmacology 2009, 34(10):2323-2328.
39. Garcia-Alloza M., Zaldua N., Diez-Ariza M., Marcos B., Lasheras B., Gil-Bea F.J., et al. Effect of selective cholinergic denervation on the serotonergic system: implications for learning and memory. Journal of Neuropathology and Experimental Neurology 2006, 65:1074-1081.
40. Heider M., Schliebs R., Roßner S., Bigl V. Basal forebrain cholinergic immunolesion by 192IgG-saporin: evidence for a presynaptic location of subpopulations of α2- and β-adregergic as well as 5-HT2A receptors on cortical cholinergic terminals. Neurochemical Research 1997, 22(8):957-966.
41. Lanctôt K.L., Herrmann N., Eryavec G., van Reekum R., Reed K., Naranjo C.A. Central serotonergic activity is related to the aggressive behaviours of Alzheimer's disease. Neuropsychopharmacology 2002, 27(4):646-654.
42. Garcia-Alloza M., Gil-Bea F.J., Diez-Ariza M., Chen C.P., Francis P.T., Lasheras B., et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 2005, 43:442-449.
43. Quinlivan M., Chalon S., Vergote J., Henderson J., Katsifis A., Kassiou M., et al. Decreased vesicular acetylcholine transporter and alpha(4)beta(2) nicotinic receptor density in the rat brain following 192 IgG-saporin immunolesioning. Neuroscience Letters 2007, 26:97-101.
44. Potter P.E., Gaughan C., Assouline Y. Lesion of septal-hippocampal neurons with 192 IgG-saporin alters function of M1 muscarinic receptors. Neuropharmacology 1999, 38:579-586.
45. Yan Z., Feng J. Alzheimer's disease: interactions between cholinergic functions and β-amyloid. Current Alzheimer Research 2004, 1:241-248.
46. Huang Z.-B., Wang H., Rao X.-R., Zhong G.-F., Hu W.-H., Sheng G.-Q. Different effects of scopolamine on the retrieval of spatial memory and fear memory. Behavioural Brain Research 2011, 221:604-609.
47. Ragozzino M.E., Kesner R.P. The effects of muscarinic receptor blockade in the rat anterior cingulate and prelimbic/infralimbic cortices on spatial working memory. Neurobiology of Learning and Memory 1998, 69:241-257.
48. Mochizuki A., Peterson J.W., Mufson E.J., Trapp B.D. Amyloid load and neural elements in Alzheimer's disease and nondemented individuals with high amyloid plaque density. Experimental Neurology 1996, 142:89-102.
49. Arendash G.W., King D.L., Gordon M.N., Morgan D., Hatcher J.M., Hope C.E., et al. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and preseniline-1 transgenes. Brain Research 2001, 891:42-53.
50. Filali M., Lalonde R. Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer's disease. Brain Research 2009, 1292:93-99.
51. Gallagher J.J., Minogue A.M., Lynch M.A. Impaired performance of female APP/PS1 mice in the Morris water maze is coupled with increased Aβ accumulation and microglial activation. Neurodegenerative Diseases 2013, 11(1):33-41.
52. Dong H., Yuede C.M., Coughlan C.A., Murphy K.M., Csernansky J.G. Effects of donepezil on amyloid-β and synapse density in the Tg2576 mouse model of Alzheimer's disease. Brain Research 2009, 1303:169-178.
53. Lee S.-T., Chu K., Park J.-E., Jung K.-H., Jeon D., Lim J.-Y., et al. Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-beta burden in Alzheimer's disease models. Journal of Neurochemistry 2012, 120:115-124.
54. Arendash G.W., King D.L. Intra- and intertask relationships in a behavioral test battery given to Tg2576 transgenic mice and controls. Physiology and Behavior 2002, 75:643-652.
55. King D.L., Arendash G.W. Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiology and Behavior 2002, 75:627-642.
56. Corcoran K.A., Lu Y., Turner R.S., Maren S. Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. Learning and Memory 2002, 9:243-252.
57. Lin L., LeBlanc C.J., Deacon T.W., Isacson O. Chronic cognitive deficits and amyloid precursor protein elevation after selective immunotoxin lesions of the basal forebrain cholinergic system. Neuroreport 1998, 16:547-552.
58. Cirrito J.R., Kang J.-E., Lee J., Stewart F.R., Verges D.K., Silverio L.M., et al. Endocytosis is required for synaptic activity-dependent release of amyloid-β in vivo. Neuron 2008, 58:42-51.
59. Gurevicius K., Lipponen A., Tanila H. Electrical brain activity in freely moving APP/PS1 transgenic mice. Program No. 241.01. 2011 neuroscience meeting planner 2011, Society for Neuroscience, Washington, DC, [online].
60. Minkeviciene R., Rheims S., Dobszay M.B., Zilberter M., Hartikainen J., Fülöp L., et al. Amyloid β-induced neuronal hyperexcitability triggers progressive epilepsy. Journal of Neuroscience 2009, 29:3453-3462.
61. Silveira D.C., Holmes G.L., Schachter S.C., Geula C., Schomer D.L. Increased susceptibility to generalized seizures after immunolesions of the basal forebrain cholinergic neurons in rats. Brain Research 2000, 878:223-227.
62. Hauser W.A., Morris M.L., Heston L.L., Anderson V.E. Seizures and myoclonus in patients with Alzheimer's disease. Neurology 1986, 36:1226-1230.
63. Gu Z., Zhong P., Yan Z. Activation of muscarinic receptors inhibits β-amyloid peptide-induced signalling in cortical slices. Journal of Biological Chemistry 2003, 278(19):17546-17556.
64. Flynn D.D., Weinstein D.A., Mash D.C. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Annals of Neurology 1991, 29:256-262.
65. Jope R.S., Song L., Li X., Powers R. Impaired phosphoinositide hydrolysis in Alzheimer's disease brain. Neurobiology of Aging 1994, 15:221-226.
66. Auld D.S., Kornecook T.J., Bastianetto S., Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition and treatment strategies. Progress in Neurobiology 2002, 68:209-245.
67. Kar S., Slowikowski S.P.M., Westaway D., Mount H.T.J. Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer's disease. Journal of Psychiatry and Neuroscience 2004, 29:427-441.
68. Wallace W.C., Bragin V., Robakis N.K., Sambamurti K., VanderPutten D., Merril C.R., et al. Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. Molecular Brain Research 1991, 10:173-178.
69. Wallace W.C., Lieberburg I., Schenk D., Vigo-Pelfrey C., Davis K.L., Haroutunian V. Chrionic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats. Journal of Neuroscience 1995, 15:4896-4905.